Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose neratinib + trastuzumab biosimilar + nab-paclitaxel as neoadjuvant therapy in HER2+/HR+ early or locally advanced breast cancer
ChiCTR2500108275Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Aug 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of neratinib in breast cancer (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: tpCR (total pathologic complete response). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
neratinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2500108275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108275.